Accuracy and precision of point-of-care testing for glucose and prothrombin time at the critical care units

Cecilia Yuoh, M. Tarek Elghetany, John R. Petersen, Amin Mohammad, Anthony Okorodudu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The use of point-of-care testing (POCT) in critical care patient units has continued to increase since the 1980s. This increase is due to the need for prompt therapeutic interventions that may impact mortality and morbidity, and reduce the overall cost of healthcare for critically ill patients. The diagnostic manufacturing industry has risen to this challenge by introducing portable and/or handheld analyzers for use at the point-of-care. In order to ensure the public safety in the USA, the Food and Drug Administration (FDA) must approve the use of each POCT analyzer. The FDA approval is based on established performance criteria that includes relative accuracy and precision documentation. This study evaluated the precision and accuracy of the POCT prothrombin time and glucose analyzers relative to the manufacturers' specifications, to the internal QC in the main laboratory, and to the results of the external proficiency-testing program. The QC for the prothrombin time had a precision that ranged from 2.84% to 3.45% (POCT) and from 1.27-1.66% (main laboratory). The precision for the glucose QC ranged from 5% to 5.2% (POCT) and 0.9-2.7% (main laboratory). Using the results of the external proficiency testing, the inter-laboratory CV% for the POCT prothrombin time ranged from 3.5% to 5.0% and the main laboratory had a range of 2.5-2.9%. The inter-laboratory CV% ranges for glucose POCT and the main laboratory were 4.9-10.6% and 1.8-3.5%, respectively. The main laboratory analyzers proved to be more accurate than the POCT analyzers as indicated by comparison to the mean prothrombin time and glucose results of all participating laboratories in the proficiency testing program.

Original languageEnglish (US)
Pages (from-to)119-123
Number of pages5
JournalClinica Chimica Acta
Volume307
Issue number1-2
DOIs
StatePublished - May 2001

Fingerprint

Prothrombin Time
Prothrombin
Critical Care
Glucose
Testing
Laboratory Proficiency Testing
United States Food and Drug Administration
Point-of-Care Systems
Drug Approval
Point-of-Care Testing
Critical Illness
Documentation
Health Care Costs
Morbidity
Safety
Mortality
Specifications

Keywords

  • AccuChek Advantage Monitor
  • Accuracy
  • CoaguChek Plus System
  • Critical care
  • Point-of-care testing
  • Precision

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Accuracy and precision of point-of-care testing for glucose and prothrombin time at the critical care units. / Yuoh, Cecilia; Tarek Elghetany, M.; Petersen, John R.; Mohammad, Amin; Okorodudu, Anthony.

In: Clinica Chimica Acta, Vol. 307, No. 1-2, 05.2001, p. 119-123.

Research output: Contribution to journalArticle

Yuoh, Cecilia ; Tarek Elghetany, M. ; Petersen, John R. ; Mohammad, Amin ; Okorodudu, Anthony. / Accuracy and precision of point-of-care testing for glucose and prothrombin time at the critical care units. In: Clinica Chimica Acta. 2001 ; Vol. 307, No. 1-2. pp. 119-123.
@article{8a305bbe3ef84d83aca5ebfeebfd9cf3,
title = "Accuracy and precision of point-of-care testing for glucose and prothrombin time at the critical care units",
abstract = "The use of point-of-care testing (POCT) in critical care patient units has continued to increase since the 1980s. This increase is due to the need for prompt therapeutic interventions that may impact mortality and morbidity, and reduce the overall cost of healthcare for critically ill patients. The diagnostic manufacturing industry has risen to this challenge by introducing portable and/or handheld analyzers for use at the point-of-care. In order to ensure the public safety in the USA, the Food and Drug Administration (FDA) must approve the use of each POCT analyzer. The FDA approval is based on established performance criteria that includes relative accuracy and precision documentation. This study evaluated the precision and accuracy of the POCT prothrombin time and glucose analyzers relative to the manufacturers' specifications, to the internal QC in the main laboratory, and to the results of the external proficiency-testing program. The QC for the prothrombin time had a precision that ranged from 2.84{\%} to 3.45{\%} (POCT) and from 1.27-1.66{\%} (main laboratory). The precision for the glucose QC ranged from 5{\%} to 5.2{\%} (POCT) and 0.9-2.7{\%} (main laboratory). Using the results of the external proficiency testing, the inter-laboratory CV{\%} for the POCT prothrombin time ranged from 3.5{\%} to 5.0{\%} and the main laboratory had a range of 2.5-2.9{\%}. The inter-laboratory CV{\%} ranges for glucose POCT and the main laboratory were 4.9-10.6{\%} and 1.8-3.5{\%}, respectively. The main laboratory analyzers proved to be more accurate than the POCT analyzers as indicated by comparison to the mean prothrombin time and glucose results of all participating laboratories in the proficiency testing program.",
keywords = "AccuChek Advantage Monitor, Accuracy, CoaguChek Plus System, Critical care, Point-of-care testing, Precision",
author = "Cecilia Yuoh and {Tarek Elghetany}, M. and Petersen, {John R.} and Amin Mohammad and Anthony Okorodudu",
year = "2001",
month = "5",
doi = "10.1016/S0009-8981(01)00442-9",
language = "English (US)",
volume = "307",
pages = "119--123",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Accuracy and precision of point-of-care testing for glucose and prothrombin time at the critical care units

AU - Yuoh, Cecilia

AU - Tarek Elghetany, M.

AU - Petersen, John R.

AU - Mohammad, Amin

AU - Okorodudu, Anthony

PY - 2001/5

Y1 - 2001/5

N2 - The use of point-of-care testing (POCT) in critical care patient units has continued to increase since the 1980s. This increase is due to the need for prompt therapeutic interventions that may impact mortality and morbidity, and reduce the overall cost of healthcare for critically ill patients. The diagnostic manufacturing industry has risen to this challenge by introducing portable and/or handheld analyzers for use at the point-of-care. In order to ensure the public safety in the USA, the Food and Drug Administration (FDA) must approve the use of each POCT analyzer. The FDA approval is based on established performance criteria that includes relative accuracy and precision documentation. This study evaluated the precision and accuracy of the POCT prothrombin time and glucose analyzers relative to the manufacturers' specifications, to the internal QC in the main laboratory, and to the results of the external proficiency-testing program. The QC for the prothrombin time had a precision that ranged from 2.84% to 3.45% (POCT) and from 1.27-1.66% (main laboratory). The precision for the glucose QC ranged from 5% to 5.2% (POCT) and 0.9-2.7% (main laboratory). Using the results of the external proficiency testing, the inter-laboratory CV% for the POCT prothrombin time ranged from 3.5% to 5.0% and the main laboratory had a range of 2.5-2.9%. The inter-laboratory CV% ranges for glucose POCT and the main laboratory were 4.9-10.6% and 1.8-3.5%, respectively. The main laboratory analyzers proved to be more accurate than the POCT analyzers as indicated by comparison to the mean prothrombin time and glucose results of all participating laboratories in the proficiency testing program.

AB - The use of point-of-care testing (POCT) in critical care patient units has continued to increase since the 1980s. This increase is due to the need for prompt therapeutic interventions that may impact mortality and morbidity, and reduce the overall cost of healthcare for critically ill patients. The diagnostic manufacturing industry has risen to this challenge by introducing portable and/or handheld analyzers for use at the point-of-care. In order to ensure the public safety in the USA, the Food and Drug Administration (FDA) must approve the use of each POCT analyzer. The FDA approval is based on established performance criteria that includes relative accuracy and precision documentation. This study evaluated the precision and accuracy of the POCT prothrombin time and glucose analyzers relative to the manufacturers' specifications, to the internal QC in the main laboratory, and to the results of the external proficiency-testing program. The QC for the prothrombin time had a precision that ranged from 2.84% to 3.45% (POCT) and from 1.27-1.66% (main laboratory). The precision for the glucose QC ranged from 5% to 5.2% (POCT) and 0.9-2.7% (main laboratory). Using the results of the external proficiency testing, the inter-laboratory CV% for the POCT prothrombin time ranged from 3.5% to 5.0% and the main laboratory had a range of 2.5-2.9%. The inter-laboratory CV% ranges for glucose POCT and the main laboratory were 4.9-10.6% and 1.8-3.5%, respectively. The main laboratory analyzers proved to be more accurate than the POCT analyzers as indicated by comparison to the mean prothrombin time and glucose results of all participating laboratories in the proficiency testing program.

KW - AccuChek Advantage Monitor

KW - Accuracy

KW - CoaguChek Plus System

KW - Critical care

KW - Point-of-care testing

KW - Precision

UR - http://www.scopus.com/inward/record.url?scp=0035036663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035036663&partnerID=8YFLogxK

U2 - 10.1016/S0009-8981(01)00442-9

DO - 10.1016/S0009-8981(01)00442-9

M3 - Article

VL - 307

SP - 119

EP - 123

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -